We serve Chemical Name:4-(Cyclooctylamino)-4-oxobutanoic acid CAS:392714-61-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(Cyclooctylamino)-4-oxobutanoic acid
CAS.NO:392714-61-3
Synonyms:hms2351l24;hms1590f21
Molecular Formula:C12H21NO3
Molecular Weight:227.30000
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:459.4ºC at 760 mmHg
Density:1.09g/cm3
Index of Refraction:1.497
PSA:66.40000
Exact Mass:227.15200
LogP:2.47120
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like hms2351l24 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,hms1590f21 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,hms1590f21 Use and application,hms2351l24 technical grade,usp/ep/jp grade.
Related News: Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity. 5,7-Diphenyl-2,3-dihydro-pyrrolo[2,1-b]thiazol-6-one manufacturers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. 3-methyl-4-(2-methylquinolin-5-yl)piperazin-1-carboxylic acid tert-butyl ester suppliers This not only makes it easier to remove enzyme residues from the desired product, but also ensures valuable high turnover enzymes can be reused multiple times without compromising their activity. 2-Chlor-1-vinyl-ethylphosphonsaeure-bis-(2-chlor-buten-(3)-ylester) vendor & factory Zynteglo, a gene therapy for the blood disorder beta thalassaemia, uses a viral vector (or modified virus) to deliver a working gene into the patient’s blood cells. ,Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company.
